Literature DB >> 30367203

Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Joanna E M Sale1,2, Matthew Gray3, Daniel Mancuso3, Taucha Inrig3, Gilles Boire4, Marie-Claude Beaulieu5, Larry Funnell6, Earl Bogoch7.   

Abstract

We examined international osteoporosis guidelines to determine the tools used to assess fracture risk, the classification of fracture risk presented, and the recommendations based on fracture risk status. We conducted a document analysis of guidelines from the International Osteoporosis Foundation (IOF) website retrieved as of May 10, 2018, focusing on guidelines written in English only. Two reviewers independently reviewed each document and the following data were extracted: (1) fracture risk tool(s) endorsed; (2) classification system used to describe fracture risk status (e.g., low, moderate, high); and (3) recommendations based on risk status (e.g., pharmacological treatment). Two additional reviewers verified all data extraction. A total of 112 guidelines were listed on the IOF website, of which 94 were located either through the provided link or through a PubMed search. Of 70 guidelines written in English, 63 guidelines discussed the concept of fracture risk of which, 39 endorsed FRAX. Twenty-eight guidelines defined fracture risk categories or thresholds which determined recommendations. In total, 26 provided a risk category or threshold which constituted an indication for pharmacotherapy. Twelve guidelines reported a moderate, medium, or intermediate risk category which was associated with variable recommendations for testing and treatment. Despite the generally accepted international shift to fracture risk as a basis for treatment decisions, the majority of guidelines in English did not provide treatment recommendations based on fracture risk status. In guidelines with recommendations based on fracture risk status, thresholds and recommendations varied making international comparisons of treatment difficult.

Entities:  

Keywords:  Drug therapy; Osteoporosis; Patient care; Risk assessment

Mesh:

Substances:

Year:  2018        PMID: 30367203     DOI: 10.1007/s00296-018-4181-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  65 in total

1.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.

Authors:  Alexandra Papaioannou; Suzanne Morin; Angela M Cheung; Stephanie Atkinson; Jacques P Brown; Sidney Feldman; David A Hanley; Anthony Hodsman; Sophie A Jamal; Stephanie M Kaiser; Brent Kvern; Kerry Siminoski; William D Leslie
Journal:  CMAJ       Date:  2010-10-12       Impact factor: 8.262

2.  Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004).

Authors:  Hajime Nawata; Satoshi Soen; Ryoichi Takayanagi; Ikuko Tanaka; Kunio Takaoka; Masao Fukunaga; Toshio Matsumoto; Yasuo Suzuki; Hiroyuki Tanaka; Saeko Fujiwara; Takami Miki; Akira Sagawa; Yoshiki Nishizawa; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

3.  The Future of Fracture Risk Assessment in the Management of Osteoporosis.

Authors:  Sanford Baim
Journal:  J Clin Densitom       Date:  2017-07-21       Impact factor: 2.617

4.  Comparison of CAROC and FRAX in Fragility Fracture Patients: Agreement, Clinical Utility, and Implications for Clinical Practice.

Authors:  Nooshin Khobzi Rotondi; Dorcas E Beaton; Victoria Elliot-Gibson; Rebeka Sujic; Robert G Josse; Joanna E M Sale; William D Leslie; Earl R Bogoch
Journal:  J Rheumatol       Date:  2016-06-15       Impact factor: 4.666

5.  Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts.

Authors:  W D Leslie; C Berger; L Langsetmo; L M Lix; J D Adachi; D A Hanley; G Ioannidis; R G Josse; C S Kovacs; T Towheed; S Kaiser; W P Olszynski; J C Prior; S Jamal; N Kreiger; D Goltzman
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

6.  Dual energy x-ray absorptiometry-based assessment of male patients using standardized bone density values and a national reference database.

Authors:  Stefan Goemaere; Dirk Vanderschueren; Jean-Marc Kaufman; Jean-Yves Reginster; Yves Boutsen; Stefaan Poriau; Joris Callens; Frank Raeman; Genevieve Depresseux; Herman Borghs; Jean-Pierre Devogelaer; Steven Boonen
Journal:  J Clin Densitom       Date:  2006-11-30       Impact factor: 2.617

7.  Guidelines for the diagnosis, prevention and management of osteoporosis.

Authors:  M Rossini; S Adami; F Bertoldo; D Diacinti; D Gatti; S Giannini; A Giusti; N Malavolta; S Minisola; G Osella; M Pedrazzoni; L Sinigaglia; O Viapiana; G C Isaia
Journal:  Reumatismo       Date:  2016-06-23

8.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

9.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women.

Authors:  J A Kanis; E V McCloskey; H Johansson; C Cooper; R Rizzoli; J-Y Reginster
Journal:  Osteoporos Int       Date:  2012-10-19       Impact factor: 4.507

10.  Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ana Patrícia Paula; Cristiano Zerbini; Diogo S Domiciano; Helenice Gonçalves; Jaime S Danowski; João F Marques Neto; Laura M C Mendonça; Mailze C Bezerra; Maria Teresa Terreri; Marta Imamura; Pedro Weingrill; Perola G Plapler; Sebastião Radominski; Tatiana Tourinho; Vera L Szejnfeld; Nathalia C Andrada
Journal:  Rev Bras Reumatol       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.